MedPath

Study on the clinical efficacy of Shi-Dan-Ke-Li in the treatment of chronic atrophic gastritis

Phase 2
Conditions
chronic atrophic gastritis
Registration Number
ITMCTR2024000145
Lead Sponsor
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1) Meet the western medical diagnostic criteria for CAG (OLGA/OLGIM stage II and above).
2) Conforms to the Chinese medicine diagnosis of CAG of the weak spleen and stomach type (spleen and stomach cold deficiency syndrome).
3) Hp negative (at least one of C13 or C14 respiratory test is required)
4) Age 18-70 (including 18 and 70 years old), gender is not limited.
5) Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.

Exclusion Criteria

1 Pregnant and lactating women
2 Endoscopy suggests gastric cancer and patients with pathologically confirmed gastric cancer, high-grade intraepithelial neoplasia, and severe heterogeneous hyperplasia.
3 Endoscopy suggests peptic ulcer patients.
4 Patients with poor adherence to medical advice or allergy to the drug.
5 Patients who cannot tolerate endoscopy
6 Patients with serious mental disorders who are unable to co-operate.
7 Patients with abnormalities in liver and kidney function and coagulation.
8Patients participating in another clinical study at the same time.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pathological observation of stomach tissue;
Secondary Outcome Measures
NameTimeMethod
PGII;G17;PGI;
© Copyright 2025. All Rights Reserved by MedPath